1-3 of 3
Kathy Delaria
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma

Siler H. Panowski, Tracy C. Kuo, Yi Zhang, Amy Chen, Tao Geng, Laura Aschenbrenner, Cris Kamperschroer, Edward Pascua, Wei Chen, Kathy Delaria, Santiago Farias, Marjorie Bateman, Russell G. Dushin, Sherman M. Chin, Thomas J. Van Blarcom, Yik Andy Yeung, Kevin C. Lindquist, Allison G. Chunyk, Bing Kuang, Bora Han, Michael Mirsky, Ingrid Pardo, Bernard Buetow, Thomas G. Martin, Jeffrey L. Wolf, David Shelton, Arvind Rajpal, Pavel Strop, Javier Chaparro-Riggers, Barbra J. Sasu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (11): 2008–2020.
https://doi.org/10.1158/1535-7163.MCT-19-0007
Published: 01 November 2019
View articletitled, Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Open the PDF for Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

Pavel Strop, Thomas-Toan Tran, Magdalena Dorywalska, Kathy Delaria, Russell Dushin, Oi Kwan Wong, Wei-Hsien Ho, Dahui Zhou, Aidong Wu, Eugenia Kraynov, Laura Aschenbrenner, Bora Han, Christopher J. O'Donnell, Jaume Pons, Arvind Rajpal, Dave L. Shelton, Shu-Hui Liu
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2698–2708.
https://doi.org/10.1158/1535-7163.MCT-16-0431
Published: 01 November 2016
View articletitled, RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
Open the PDF for RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

Magdalena Dorywalska, Russell Dushin, Ludivine Moine, Santiago E. Farias, Dahui Zhou, Thayalan Navaratnam, Victor Lui, Adela Hasa-Moreno, Meritxell Galindo Casas, Thomas-Toan Tran, Kathy Delaria, Shu-Hui Liu, Davide Foletti, Christopher J. O'Donnell, Jaume Pons, David L. Shelton, Arvind Rajpal, Pavel Strop
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (5): 958–970.
https://doi.org/10.1158/1535-7163.MCT-15-1004
Published: 05 May 2016
View articletitled, Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Open the PDF for Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design in another window
Includes: Supplementary data